A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)

Abstract Background Equivalent efficacy and comparable pharmacokinetic, immunogenicity, and safety profiles of the biosimilar BAT1806/BIIB800 and reference tocilizumab (TCZ) in participants with moderate-to-severe rheumatoid arthritis (RA) have been reported up to week 24 (treatment period [TP] 1) o...

詳細記述

書誌詳細

主要な著者:	Xiaomei Leng, Piotr Leszczyński, Slawomir Jeka, Shengyun Liu, Huaxiang Liu, Malgorzata Miakisz, Jieruo Gu, Lali Kilasonia, Mykola Stanislavchuk, Xiaolei Yang, Yinbo Zhou, Qingfeng Dong, Marian Mitroiu, Janet Addison, Mourad F. Rezk, Xiaofeng Zeng
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2024-09-01
シリーズ:	Arthritis Research & Therapy
主題:	Rheumatoid arthritis Biosimilar pharmaceuticals Tocilizumab Treatment switching
オンライン･アクセス:	https://doi.org/10.1186/s13075-024-03375-w
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!